Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M245,236Revenue $M53,634Net Margin (%)18.5Z-Score4.2
Enterprise Value $M252,051EPS $4.1Operating Margin %21.4F-Score6
P/E(ttm))25.5Cash Flow Per Share $0Pre-tax Margin (%)23.6Higher ROA y-yY
Price/Book3.410-y EBITDA Growth Rate %1.3Quick Ratio1.2Cash flow > EarningsY
Price/Sales4.65-y EBITDA Growth Rate %-0.6Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %14.2ROA % (ttm)8.1Higher Current Ratio y-yY
Dividend Yield %2.6Insider Buy (3m)0ROE % (ttm)14.3Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M2,399ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 102.249%Sold Out0
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 102.2412%Reduce -98.51%9,646
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 102.2412%New holding7,772
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 102.2414%Reduce -71.80%649,519
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 102.2414%Add 10.04%51,102,219
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 102.2428%Sold Out0
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 102.2429%Sold Out0
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 102.2434%Reduce -85.39%726,200
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 102.2434%Reduce -21.03%33,456
NVSVanguard Health Care Fund 2012-12-31 Reduce-0.99%$58.97 - $63.96
($61.82)
$ 102.2440%Reduce -70.59%1,461,400
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 102.2440%Add 2.65%48,438,459
NVSIrving Kahn 2012-12-31 Add0.04%$58.97 - $63.96
($61.82)
$ 102.2440%Add 10.43%42,368
NVSHOTCHKIS & WILEY 2012-12-31 Reduce-0.02%$58.97 - $63.96
($61.82)
$ 102.2440%Reduce -1.98%2,313,613
NVSKen Fisher 2012-12-31 Reduce-0.01%$58.97 - $63.96
($61.82)
$ 102.2440%Reduce -0.93%5,038,879
NVSTweedy Browne 2012-12-31 Reduce$58.97 - $63.96
($61.82)
$ 102.2440%Reduce -0.09%301,399
NVSChris Davis 2012-12-31 Reduce$58.97 - $63.96
($61.82)
$ 102.2440%Reduce -0.09%33,100
NVSKen Fisher 2012-09-30 Buy 0.86%$55.24 - $61.51
($58.49)
$ 102.2443%New holding5,086,362
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 102.2443%Add 3.23%47,187,759
NVSMichael Price 2012-03-31 Sold Out -1.3%$53.31 - $58.33
($52.37)
$ 102.2449%Sold Out0
NVSKen Fisher 2012-03-31 Sold Out -0.13%$53.31 - $58.33
($52.37)
$ 102.2449%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15582.27view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
      Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Anacor Pharmaceuticals’ Q4 Was A Solid One For Investors Mar 16 2015 
      AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
      Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
      Novartis Goes A Step Forward In Treating Lung Cancer Mar 02 2015 
      Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
      Can These Three BioTech Companies Make It Big? Feb 20 2015 
      Pfizer Takes A Giant Leap In Treatment of Cancer Feb 12 2015 


      More From Other Websites
      What you need to know before buying into Europe Apr 13 2015
      2:29 am Novartis reports Gilenya data at AAN to highlight Novartis leadership in innovation with new... Apr 13 2015
      Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods... Apr 13 2015
      Business decency for dummies: 10 lessons from the Pao trial Apr 10 2015
      AstraZeneca's Onglyza Ups Risk Of Death, FDA Says Apr 10 2015
      Putin vs. The Accountant Apr 10 2015
      Container Store's Virtue vs. Profit Apr 10 2015
      The Forever Pill: Novartis's Quest for an Anti-Aging Drug Apr 10 2015
      The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead -... Apr 09 2015
      Why Kina Grannis Chose YouTube Over Record Label Apr 08 2015
      Patent dispute settlement to benefit Penn cancer therapy partnership Apr 07 2015
      Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched Apr 07 2015
      Big pharma turns to small biotechs for edge in cancer treatment Apr 07 2015
      Juno Therapeutics Settles Patent Dispute With Novartis Apr 06 2015
      GlaxoSmithKline to move 150 Cambridge vaccine research jobs out of state Apr 03 2015
      Proteon founder Franano links InvestMidwest's past and future Apr 02 2015
      The Eyes Have It? Novartis is Accused of Interfering With Trials for Avastin Apr 02 2015
      GlaxoSmithKline to open global R&D center in Rockville Apr 02 2015
      Wave Of Biosimilars Set To Roil Pharma Apr 01 2015
      Why Is Pfizer’s Revenue Stream Declining? Apr 01 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK